Q1 Earnings Estimate for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Equities research analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for shares of Longeveron in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.37) per share for the quarter, up from their prior estimate of ($0.40). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.31) EPS.

Several other equities analysts also recently weighed in on LGVN. Roth Mkm began coverage on Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 price objective for the company. Roth Capital raised Longeveron to a “strong-buy” rating in a research report on Thursday, December 5th.

Longeveron Trading Up 5.3 %

Shares of LGVN stock opened at $1.40 on Thursday. The company has a market cap of $20.77 million, a price-to-earnings ratio of -0.22 and a beta of 0.36. The stock has a 50 day simple moving average of $1.64 and a 200-day simple moving average of $1.89. Longeveron has a 12-month low of $0.77 and a 12-month high of $6.40.

Institutional Trading of Longeveron

Several hedge funds and other institutional investors have recently bought and sold shares of LGVN. Geode Capital Management LLC increased its holdings in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the last quarter. Virtu Financial LLC acquired a new position in Longeveron in the fourth quarter valued at approximately $53,000. Jane Street Group LLC acquired a new position in Longeveron in the fourth quarter valued at approximately $35,000. Northern Trust Corp acquired a new position in Longeveron in the fourth quarter valued at approximately $31,000. Finally, State Street Corp acquired a new position in Longeveron in the third quarter valued at approximately $29,000. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.